| Intrinsic defect of the immune system in children with Down syndrome: a review MAA Kusters, RHJ Verstegen, EFA Gemen, E De Vries Clinical & Experimental Immunology 156 (2), 189-193, 2009 | 315 | 2009 |
| Down syndrome B-lymphocyte subpopulations, intrinsic defect or decreased T-lymphocyte help RHJ Verstegen, MAA Kusters, EFA Gemen, E De Vries Pediatric Research 67 (5), 563-569, 2010 | 112 | 2010 |
| Both normal memory counts and decreased naive cells favor intrinsic defect over early senescence of Down syndrome T lymphocytes MAA Kusters, EFA Gemen, RHJ Verstegen, PC Wever, E de Vries Pediatric research 67 (5), 557-562, 2010 | 67 | 2010 |
| Defective B-cell memory in patients with Down syndrome RHJ Verstegen, GJ Driessen, SJW Bartol, CJM Van Noesel, L Boon, ... Journal of allergy and clinical immunology 134 (6), 1346-1353. e9, 2014 | 62 | 2014 |
| Pediatric cannabis intoxication trends in the pre and post-legalization era N Cohen, L Galvis Blanco, A Davis, A Kahane, M Mathew, S Schuh, ... Clinical Toxicology 60 (1), 53-58, 2022 | 46 | 2022 |
| Clinical implications of immune‐mediated diseases in children with Down syndrome RHJ Verstegen, KJJ Chang, MAA Kusters Pediatric allergy and immunology 31 (2), 117-123, 2020 | 43 | 2020 |
| Drugs in lactation RHJ Verstegen, S Ito Journal of Obstetrics and Gynaecology Research 45 (3), 522-531, 2019 | 42 | 2019 |
| Down syndrome: is it really characterized by precocious immunosenescence? MAA Kusters, RHJ Verstegen, E De Vries Aging and disease 2 (6), 538, 2011 | 42 | 2011 |
| Infant drug exposure via breast milk RHJ Verstegen, PO Anderson, S Ito British Journal of Clinical Pharmacology 88 (10), 4311-4327, 2022 | 39 | 2022 |
| Inborn errors of adaptive immunity in Down syndrome RHJ Verstegen, MAA Kusters Journal of Clinical Immunology 40 (6), 791-806, 2020 | 38 | 2020 |
| Significant impact of recurrent respiratory tract infections in children with D own syndrome RHJ Verstegen, HBM van Gameren‐Oosterom, M Fekkes, E Dusseldorp, ... Child: care, health and development 39 (6), 801-809, 2013 | 35 | 2013 |
| Assessment of the implementation of pharmacogenomic testing in a pediatric tertiary care setting I Cohn, R Manshaei, E Liston, JBA Okello, R Khan, MR Curtis, AJ Krupski, ... JAMA network open 4 (5), e2110446-e2110446, 2021 | 32 | 2021 |
| Autoinflammation due to homozygous S208 MEFV mutation Y Hong, ASI Standing, S Nanthapisal, N Sebire, S Jolles, E Omoyinmi, ... Annals of the rheumatic diseases 78 (4), 571-573, 2019 | 32 | 2019 |
| Impact of Down syndrome on the performance of neonatal screening assays for severe primary immunodeficiency diseases RH Verstegen, S Borte, LA Bok, PH Van Zwieten, U von Döbeln, ... J Allergy Clin Immunol 133 (4), 1208-1211, 2014 | 29 | 2014 |
| Towards therapeutic drug monitoring of TNF inhibitors for children with juvenile idiopathic arthritis: a scoping review RHJ Verstegen, R McMillan, BM Feldman, S Ito, RM Laxer Rheumatology 59 (2), 386-397, 2020 | 24 | 2020 |
| Epidemiology of respiratory symptoms in children with Down syndrome: a nationwide prospective web-based parent-reported study RHJ Verstegen, RWNM van Hout, E de Vries BMC pediatrics 14, 1-5, 2014 | 22 | 2014 |
| Repair of surgically created diaphragmatic defect in rat with use of a crosslinked porous collagen scaffold KM Brouwer, WF Daamen, D Reijnen, RH Verstegen, G Lammers, ... Journal of Tissue Engineering and Regenerative Medicine 7 (7), 552-561, 2013 | 21 | 2013 |
| Increased circulating apoptotic lymphocytes in children with Down syndrome EFA Gemen, RHJ Verstegen, J Leuvenink, E de Vries Pediatric Blood & Cancer 59 (7), 1310-1312, 2012 | 20 | 2012 |
| The future of precision medicine RHJ Verstegen, S Ito Clinical Pharmacology & Therapeutics 106 (5), 903-906, 2019 | 16 | 2019 |
| Lymphatic edema in congenital disorders of glycosylation RHJ Verstegen, M Theodore, H van de Klerk, E Morava JIMD Reports-Case and Research Reports, 2012/1, 113-116, 2012 | 16 | 2012 |
Shinya ItoProfessor of Pediatrics and Pharmacology, Hospital for Sick Children, University of Toronto在 sickkids.ca 的电子邮件经过验证
